ISPC iSpecimen Inc

iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for biomedical research with a network of healthcare specimen providers, announced today that the Company has added several new infectious disease specimen providers to its global supply network.

These new collaborations will enable iSpecimen to connect researchers with additional providers of essential human tissue and biofluids required for infectious disease research, such as types of Influenza viruses, common and severe respiratory viruses, Lyme disease, sexually transmitted infections (STIs), sexually transmitted diseases (STDs) and other infectious diseases. Researchers will have access to clinically collected samples, banked tissues and custom collections of biospecimens, including viral positives and health control swabs, saliva, serum and plasma.

“The iSpecimen Marketplace®’s large network provides access to high volumes of samples with associated data that supports infectious disease research efforts as well as the unique needs of diagnostic companies,” said Tracy Curley, iSpecimen’s CEO. “Our global network, combined with our custom project capabilities, provides researchers with diverse samples — including those from hard-to-reach populations — to advance diagnostic test and treatment development, ultimately leading to improved patient outcomes.”

iSpecimen’s custom collection protocol matches researchers’ exact sample requirements to an ideal collection site, considering factors such as geographic location, target patient populations and legal requirements. Additionally, the Company is now able to facilitate custom collections for seasonal strains of applicable viruses through the iSpecimen Marketplace®.

About iSpecimeniSpecimen (Nasdaq: ISPC) offers an online marketplace for human biospecimens, connecting scientists in commercial and non-profit organizations with healthcare providers who have access to patients and specimens needed for medical discovery. Proprietary, cloud-based technology enables scientists to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers and other healthcare organizations. For more information, please visit www.ispecimen.com.

Forward Looking Statements

This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are characterized by future or conditional verbs such as "may," "will," "expect," "intend," "anticipate," “believe," "estimate" and "continue" or similar words. You should read statements that contain these words carefully because they discuss future expectations and plans, which contain projections of future results of operations or financial condition or state other forward-looking information.

Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to the risk factors contained in the Company's filings with the Securities and Exchange Commission, which are available for review at www.sec.gov. Forward-looking statements speak only as of the date they are made. New risks and uncertainties arise over time, and it is not possible for the Company to predict those events or how they may affect the Company. If a change to the events and circumstances reflected in the Company's forward-looking statements occurs, the Company's business, financial condition and operating results may vary materially from those expressed in the Company's forward-looking statements.

Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

For further information, please contact:

Investor ContactsKCSA Strategic CommunicationsPhil Carlson / Erika Kay iSpecimen@kcsa.com

Media ContactsKCSA Strategic CommunicationsRaquel Cona / Shana Marino iSpecimen@kcsa.com